JP2022546457A5 - - Google Patents

Info

Publication number
JP2022546457A5
JP2022546457A5 JP2022513373A JP2022513373A JP2022546457A5 JP 2022546457 A5 JP2022546457 A5 JP 2022546457A5 JP 2022513373 A JP2022513373 A JP 2022513373A JP 2022513373 A JP2022513373 A JP 2022513373A JP 2022546457 A5 JP2022546457 A5 JP 2022546457A5
Authority
JP
Japan
Prior art keywords
receptor
domain
car
liver
sequence numbers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546457A (ja
Filing date
Publication date
Priority claimed from GBGB1912515.2A external-priority patent/GB201912515D0/en
Application filed filed Critical
Publication of JP2022546457A publication Critical patent/JP2022546457A/ja
Publication of JP2022546457A5 publication Critical patent/JP2022546457A5/ja
Priority to JP2025178768A priority Critical patent/JP2026016543A/ja
Pending legal-status Critical Current

Links

JP2022513373A 2019-08-30 2020-08-28 改変された制御性ｔ細胞 Pending JP2022546457A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025178768A JP2026016543A (ja) 2019-08-30 2025-10-23 改変された制御性ｔ細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1912515.2A GB201912515D0 (en) 2019-08-30 2019-08-30 Engineered regulatory T cell
GB1912515.2 2019-08-30
PCT/GB2020/052076 WO2021038249A1 (en) 2019-08-30 2020-08-28 Engineered regulatory t cell

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025178768A Division JP2026016543A (ja) 2019-08-30 2025-10-23 改変された制御性ｔ細胞

Publications (2)

Publication Number Publication Date
JP2022546457A JP2022546457A (ja) 2022-11-04
JP2022546457A5 true JP2022546457A5 (enExample) 2023-09-04

Family

ID=68207135

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513373A Pending JP2022546457A (ja) 2019-08-30 2020-08-28 改変された制御性ｔ細胞
JP2025178768A Pending JP2026016543A (ja) 2019-08-30 2025-10-23 改変された制御性ｔ細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025178768A Pending JP2026016543A (ja) 2019-08-30 2025-10-23 改変された制御性ｔ細胞

Country Status (10)

Country Link
US (1) US20230134301A1 (enExample)
EP (1) EP4021484A1 (enExample)
JP (2) JP2022546457A (enExample)
KR (1) KR20220051390A (enExample)
CN (1) CN114585730A (enExample)
AU (1) AU2020338290A1 (enExample)
CA (1) CA3148676A1 (enExample)
GB (1) GB201912515D0 (enExample)
IL (1) IL290830A (enExample)
WO (1) WO2021038249A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202217541D0 (en) * 2022-11-24 2023-01-11 Quell Therapeutics Ltd Recombinant receptor
EP4442322A1 (en) 2023-04-06 2024-10-09 Medizinische Hochschule Hannover Liver-specific car for use against immunologic rejection
CN118001381B (zh) * 2024-01-24 2025-04-22 首都医科大学附属北京地坛医院 一种药物组合物及应用
WO2026027876A1 (en) * 2024-07-29 2026-02-05 Quell Therapeutics Limited Chimeric antigen receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
JP2013516967A (ja) * 2010-01-14 2013-05-16 グラクソ グループ リミテッド 肝臓標的化ドメイン抗体
GB201108236D0 (en) * 2011-05-17 2011-06-29 Ucl Business Plc Method
CN105713881B (zh) * 2014-12-04 2019-12-06 科济生物医药（上海）有限公司 双靶向gpc3和asgpr1的转基因免疫效应细胞及其应用
US10336810B2 (en) * 2015-02-12 2019-07-02 University Health Network Chimeric antigen receptors, encoding nucleic acids and methods of use thereof
EP3331918A1 (en) * 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
AU2016427822B2 (en) * 2016-10-31 2025-01-23 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogennous FOXP3 gene
CA3088832A1 (en) * 2018-01-19 2019-07-25 Miltenyi Biotec B.V. & Co. KG Regulatory t cell expressing a chimeric antigen receptor
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells

Similar Documents

Publication Publication Date Title
US20230406953A1 (en) Chimeric antigen receptors targeting tumor antigens
JP2026016543A5 (enExample)
JP7269249B2 (ja) Ｉｌ２ｒベータ／共通ガンマ鎖抗体
US10259874B2 (en) Anti-TIM-3 antibodies
PT2321352E (pt) Composições monovalentes para ligação a cd28 e métodos de utilização
WO2007033230A2 (en) Anti-cd3 antibody formulations
BR112020011310A2 (pt) anticorpos contra fcrn e seus métodos de uso
JP7461875B2 (ja) 病気の症状の治療又は予防に使用するための抗アドレノメデュリン（ａｄｍ）バインダー
CN116789820A (zh) 一种新型免疫调节剂的开发和应用
JP7768674B2 (ja) 膵島細胞の増殖を促進する方法
JP6599916B2 (ja) 抗Ｏｒａｉ１抗体
JP2024509557A (ja) ＮＫｐ４６に対する抗体とその応用
US20100233157A1 (en) Human antibodies against human fas and their use
JP7574692B2 (ja) 二重特異性抗体
WO2024188341A1 (zh) 特异性结合Claudin18.2的抗体及其制法和应用
WO2010132872A1 (en) Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
CN116854820B (zh) Pd-1非阻断性清除抗体及其用途
WO2024225446A1 (ja) 新規なＮａｖ１．７モノクローナル抗体を含む医薬組成物
CN121285574A (zh) 特异性结合cll1的抗体及其制法和应用
WO2023186113A1 (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
JP2018024615A (ja) Ｈｔｌｖ−１関連炎症性疾患を治療する医薬組成物
WO2019072274A1 (zh) 一种激动型4-1bb单克隆抗体
US20250281538A1 (en) Compositions targeting gpc2 and gpc3 and their use for treating solid tumors
WO2025089399A1 (ja) インターロイキン７受容体（ｉｌ－７ｒ）に対する抗体および当該抗体を含む抗体薬物コンジュゲート（ａｄｃ）
JP2021155343A (ja) 肺高血圧症の予防又は治療薬